Shares of Teradata Corp (NYSE: TDC) increased greatly in pre-market trading after the business reported better-than-expected third-quarter monetary outcomes and raised its FY25 EPS assistance above price quotes. Likewise, the business released fourth-quarter EPS assistance above price quotes.
Teradata reported quarterly revenues of 72 cents per share which beat the expert agreement price quote of 54 cents per share. The business reported quarterly sales of $416.000 million which beat the expert agreement price quote of $406.228 million.
Teradata shares leapt 14.6% to $23.73 in the pre-market trading session.
Here are some other stocks relocating pre-market trading.
Gainers
- SMX (Security Matters) Public Limited Business (NASDAQ: SMX) acquired 70% to $2.50 in pre-market trading after SMX and CARTIF participated in non-binding LOI to incorporate SMX’s end-to-end tracing platform into CARTIF’s portfolio and Market 5.0 jobs
- Nuvve Holding Corp. (NASDAQ: NVVE) increased 41.3% to $0.2969 in pre-market trading. Nuvve Holding will offer 3rd quarter upgrade on Thursday, Nov. 13.
- Babcock & & Wilcox Enterprises, Inc (NYSE: BW) rose 29.1% to $4.83 in pre-market trading. B&W launched 4 statements on Tuesday: a $1.5 billion AI information center agreement with Applied Digital Corp. (NASDAQ: APLD), third-quarter revenues outcomes, the $29 million sale of the Allen-Sherman-Hoff organization, and prepares to redeem all staying February 2026 bonds.
- Entravision Communications Corporation (NYSE: EVC) rose 28.8% to $2.55 in pre-market trading after the business reported a year-over-year boost in third-quarter monetary outcomes.
- DirectBooking Innovation Co., Ltd. (NASDAQ: ZDAI) acquired 28.8% to $0.5829 in pre-market trading.
- Digital Turbine, Inc (NASDAQ: APPS) acquired 26.2% to $7.47 in pre-market trading after the business reported better-than-expected second-quarter monetary outcomes and raised its FY26 sales assistance above price quotes.
- Kennedy-Wilson Holdings, Inc. (NYSE: KW) rose 23.2% to $9.20 in pre-market trading after CEO William McMorrow and Fairfax Financial sent a proposition to obtain the business for $10.25 per share in money.
- Rigel Pharmaceuticals Inc (NASDAQ: RIGL) acquired 23.2% to $35.05 in pre-market trading after the business reported better-than-expected third-quarter monetary outcomes and raised its FY25 sales assistance above price quotes.
- Lumentum Holdings Inc (NASDAQ: LITE) increased 13.5% to $214.00 in pre-market trading after the business reported better-than-expected first-quarter monetary outcomes and released second-quarter assistance above price quotes.
Losers
- Biohaven Ltd (NYSE: BHVN) toppled 46.2% to $7.51 in pre-market trading. Biohaven got FDA Total Reaction Letter for VYGLXIA following favorable real-world proof revealing 50– 70% slowing down of spinocerebellar ataxia illness development.
- Trex Business Inc ( NYSE: TREX) decreased 31.9% to $32.02 in pre-market trading after the business reported worse-than-expected third-quarter monetary outcomes and released fourth-quarter sales assistance listed below price quotes. Likewise, the business cut its FY25 sales assistance listed below price quotes.
- Soleno Therapies Inc (NASDAQ: SLNO) fell 22.2% to $49.65 in pre-market trading following third-quarter outcomes.
- Axon Business Inc (NASDAQ: AXON) fell 19.6% to $567.50 in pre-market trading after the business reported combined third-quarter monetary outcomes. The business signed a contract to obtain Carbyne.
- Akari Therapies PLC (NASDAQ: AKTX) shares dipped 19.2% to $0.66 in pre-market trading after acquiring 13% on Tuesday.
- Pinterest Inc (NYSE: PINS) dipped 18.8% to $26.69 in pre-market trading after the business published downbeat revenues for the 3rd quarter.
- SSR Mining Inc (NASDAQ: SSRM) fell 17.5% to $17.90 in pre-market trading after publishing third-quarter outcomes.
- Uniqure NV (NASDAQ: QURE) fell 15.8% to $25.61 in pre-market trading after acquiring 13% on Monday.
- Clover Health Investments Corp (NASDAQ: CLOV) fell 15.5% to $2.97 in pre-market trading after the business reported combined third-quarter monetary outcomes.
- Uniqure NV (NASDAQ: QURE) dipped 11.6% to $30.30 in pre-market trading. The U.S. Fda (FDA) on Monday supplied feedback to uniQure concerning its investigational gene treatment for Huntington’s illness.
Now Read This:
Image through Shutterstock
Market News and Data gave you by Benzinga APIs